Return to homepagePandemic Pact

Evaluation of the performance of stool and urine metagenomic NGS analysis for the diagnosis of unexplained diseases in immunocompromised patients and for surveillance of emerging diseases

  • Funded by Agence nationale de recherche sur le sida et les hépatites virale [National Agency for AIDS Research] (ANRS)
  • Total publications:0 publications

Grant number: ECTZ292183

Grant search

Key facts

  • Disease

    Disease X

  • Start & end year

    2024
    2026

  • Known Financial Commitments (USD)

    $481,559.83

  • Funder

    Agence nationale de recherche sur le sida et les hépatites virale [National Agency for AIDS Research] (ANRS)

  • Principal Investigator

    FOURGEAUD Jacques

  • Research Location

    France

  • Lead Research Institution

    N/A

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Diagnostics

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Individuals with multimorbidity

  • Occupations of Interest

    Unspecified

Abstract

"Primary objective: Evaluation of ""causative" or "possibly causative pathogen"" detection rate by mNGS in noninvasive samples (stool and/or urine) compared to invasive reference samples (blood, CSF, BAL and/or tissue). Secondary objectives: 1. Among detected ""causative" or "possibly causative pathogen"", evaluation of emergent or reemergent pathogen (including previously unknown pathogen X) detection rates by mNGS in non-invasive samples (stool and/or urine) compared to invasive reference samples (blood, CSF, BAL and/or tissue). 2. Evaluation of the impact of stool and urine mNGS results on patient management. 3. Confirmation of the role of the detected "possibly causative" pathogen in the patient's symptoms using additional investigations 4. Evaluation of ""causative" or "possibly causative" pathogen detection rates by mNGS in noninvasive samples (stool and urine) according to symptoms 5. Evaluation of ""causative" or "possibly causative" pathogen detection rates by mNGS in noninvasive samples (stool and urine) according to immune deficiency type 6. Evaluation of the cost of adding mNGS analysis in stools and urine"